Nasdaq · CIK 0000318154 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Amgen Inc.
AMGN chart by TradingView
PRICE HISTORY
LIVE · NASDAQAMGN chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $36.8B
- EBITDA
- $14.2B
- FREE CASH FLOW
- $8.1B
- EPS
- $14.23
- GROSS MARGIN
- 67.25%
- ROIC
- 14.24%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
22.5x
+36%14.1x64.4x
⤢
P / SALES (TTM)
5.2x
-7%4.2x6.2x
⤢
P / BOOK
16.9x
+313%3.7x145.5x
⤢
EV / EBITDA (TTM)
14.9x
+9%11.2x19.4x
⤢
EV / REVENUE (TTM)
6.3x
-10%5.5x7.4x
⤢
FCF YIELD (TTM)
5.17%
-1.7pp3.24%8.97%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$10.1B
+73%⤢
EBITDA (DERIVED)
$4.6B
+60%⤢
NET INCOME
$2.4B
+18%⤢
EPS (DILUTED)
$4.37
+63%⤢
REVENUE GROWTH YOY
9.53%
+8.0pp-4.22%23.18%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
34.70%
-8.2pp3.53%57.09%
⤢
RETURN ON CAPITAL
15.90%
+3.8pp3.49%27.53%
⤢
RETURN ON EQUITY (TTM)
74.80%
+50.1pp7.84%624.78%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN72.04%
OPERATING MARGIN34.95%
NET MARGIN23.62%
FCF MARGIN34.70%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$3.5B
+40%⤢
STOCK-BASED COMP
$0.2B
+99%⤢
CAPITAL EXPENDITURE
$0.5B
+207%⤢
SHARES OUTSTANDING
0.54B
-28%⤢
DIVIDEND / SHARE
—
+91%BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$14.0B
+301%⤢
TOTAL DEBT
$57.3B
+62%⤢
DEBT / EBITDA (TTM)
3.6x
+16%2.5x5.5x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 85.45%INSIDERS 0.22%OTHER / RETAIL 14.33%3,952 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 8.71% | 47.1M | $19.36B | -0.6% |
| Vanguard Capital Management LLC | 6.48% | 35.0M | $14.39B | NEW |
| State Street Corporation | 5.65% | 30.5M | $12.55B | -0.1% |
| Capital World Investors | 5.42% | 29.3M | $12.04B | +26.8% |
| Invesco Ltd. | 2.94% | 15.9M | $6.53B | -5.9% |
| Morgan Stanley | 2.93% | 15.8M | $6.51B | +0.6% |
| Geode Capital Management, LLC | 2.85% | 15.4M | $6.34B | +7.9% |
| Vanguard Portfolio Management LLC | 2.70% | 14.6M | $6.01B | NEW |
| Charles Schwab Investment Management, Inc. | 2.36% | 12.8M | $5.25B | +8.1% |
| Primecap Management Company | 1.64% | 8.9M | $3.65B | -0.3% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.